Communications Biology (Aug 2022)
PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19
- James Logue,
- Arup R. Chakraborty,
- Robert Johnson,
- Girija Goyal,
- Melissa Rodas,
- Louis J. Taylor,
- Lauren Baracco,
- Marisa E. McGrath,
- Robert Haupt,
- Brooke A. Furlong,
- Mercy Soong,
- Pranav Prabhala,
- Viktor Horvath,
- Kenneth E. Carlson,
- Stuart Weston,
- Donald E. Ingber,
- Melvin L. DePamphilis,
- Matthew B. Frieman
Affiliations
- James Logue
- Department of Microbiology and Immunology, University of Maryland, School of Medicine
- Arup R. Chakraborty
- Division of Developmental Biology, National Institute of Child Health & Human Development, National Institutes of Health
- Robert Johnson
- Department of Microbiology and Immunology, University of Maryland, School of Medicine
- Girija Goyal
- Wyss Institute for Biologically Inspired Engineering, Harvard University
- Melissa Rodas
- Wyss Institute for Biologically Inspired Engineering, Harvard University
- Louis J. Taylor
- Department of Microbiology and Immunology, University of Maryland, School of Medicine
- Lauren Baracco
- Department of Microbiology and Immunology, University of Maryland, School of Medicine
- Marisa E. McGrath
- Department of Microbiology and Immunology, University of Maryland, School of Medicine
- Robert Haupt
- Department of Microbiology and Immunology, University of Maryland, School of Medicine
- Brooke A. Furlong
- Wyss Institute for Biologically Inspired Engineering, Harvard University
- Mercy Soong
- Wyss Institute for Biologically Inspired Engineering, Harvard University
- Pranav Prabhala
- Wyss Institute for Biologically Inspired Engineering, Harvard University
- Viktor Horvath
- Wyss Institute for Biologically Inspired Engineering, Harvard University
- Kenneth E. Carlson
- Wyss Institute for Biologically Inspired Engineering, Harvard University
- Stuart Weston
- Department of Microbiology and Immunology, University of Maryland, School of Medicine
- Donald E. Ingber
- Wyss Institute for Biologically Inspired Engineering, Harvard University
- Melvin L. DePamphilis
- Division of Developmental Biology, National Institute of Child Health & Human Development, National Institutes of Health
- Matthew B. Frieman
- Department of Microbiology and Immunology, University of Maryland, School of Medicine
- DOI
- https://doi.org/10.1038/s42003-022-03766-2
- Journal volume & issue
-
Vol. 5,
no. 1
pp. 1 – 9
Abstract
Compound-testing in a murine model for COVID-19 show that the prophylactic or therapeutic application of Apilimod and other PIKfyve inhibitors, the former being considered for human Phase II trials, worsens disease outcome with higher lung viral load and mortality.
